These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 22932130)

  • 21. Targeted therapies for non-small cell lung cancer.
    Spicer J; Harper P
    Int J Clin Pract; 2005 Sep; 59(9):1055-62. PubMed ID: 16115182
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety profiles of erlotinib therapy in patients with advanced non-small-cell lung cancer.
    Hotta K; Kiura K
    Expert Rev Anticancer Ther; 2011 Jul; 11(7):991-7. PubMed ID: 21806322
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tyrosine kinase inhibitors for non-small-cell lung cancer: finding patients who will be responsive.
    Santarpia M; Altavilla G; Salazar MF; Magri I; Pettineo G; Benecchi S; Rosell R
    Expert Rev Respir Med; 2011 Jun; 5(3):413-24. PubMed ID: 21702662
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The current situation: erlotinib (Tarceva) and gefitinib (Iressa) in non-small cell lung cancer.
    Comis RL
    Oncologist; 2005 Aug; 10(7):467-70. PubMed ID: 16079313
    [No Abstract]   [Full Text] [Related]  

  • 25. Rationale and design of MARQUEE: a phase III, randomized, double-blind study of tivantinib plus erlotinib versus placebo plus erlotinib in previously treated patients with locally advanced or metastatic, nonsquamous, non-small-cell lung cancer.
    Scagliotti GV; Novello S; Schiller JH; Hirsh V; Sequist LV; Soria JC; von Pawel J; Schwartz B; Von Roemeling R; Sandler AB
    Clin Lung Cancer; 2012 Sep; 13(5):391-5. PubMed ID: 22440336
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Economic analysis: randomized placebo-controlled clinical trial of erlotinib in advanced non-small cell lung cancer.
    Bradbury PA; Tu D; Seymour L; Isogai PK; Zhu L; Ng R; Mittmann N; Tsao MS; Evans WK; Shepherd FA; Leighl NB;
    J Natl Cancer Inst; 2010 Mar; 102(5):298-306. PubMed ID: 20160168
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Targeted therapies in the treatment of advanced non-small-cell lung cancer: update.
    Mendoza L
    Klin Onkol; 2009; 22(4):131-8. PubMed ID: 19731875
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Erlotinib: small-molecule targeted therapy in the treatment of non-small-cell lung cancer.
    Smith J
    Clin Ther; 2005 Oct; 27(10):1513-34. PubMed ID: 16330289
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Testing for anaplastic lymphoma kinase rearrangement to target crizotinib therapy: oncology, pathology and health economic perspectives.
    Lee JA; Bubendorf L; Stahel R; Peters S
    Expert Rev Anticancer Ther; 2013 May; 13(5):625-36. PubMed ID: 23617353
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Crizotinib: a drug that crystallizes a unique molecular subset of non-small-cell lung cancer.
    Ou SH
    Expert Rev Anticancer Ther; 2012 Feb; 12(2):151-62. PubMed ID: 22316363
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Epidermal growth factor receptor mutations and tyrosine kinase inhibitor therapy in advanced non-small-cell lung cancer.
    Technol Eval Cent Assess Program Exec Summ; 2011 Mar; 25(6):1-5. PubMed ID: 21638942
    [No Abstract]   [Full Text] [Related]  

  • 32. Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer.
    Sequist LV; Bell DW; Lynch TJ; Haber DA
    J Clin Oncol; 2007 Feb; 25(5):587-95. PubMed ID: 17290067
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Therapeutic impact of molecular diagnosis in metastatic non-small cell lung cancer: targeted therapies in 2013].
    Pecuchet N; Bigot F; Henni M; Fabre E
    Rev Pneumol Clin; 2014; 70(1-2):38-46. PubMed ID: 24566025
    [TBL] [Abstract][Full Text] [Related]  

  • 34. First-line crizotinib shows promise in patients with NSCLC.
    Bagcchi S
    Lancet Respir Med; 2015 Jan; 3(1):17. PubMed ID: 25497281
    [No Abstract]   [Full Text] [Related]  

  • 35. In search of the philosopher’s stone: The ALCHEMIST study for lung cancer.
    Veeramachaneni N; Wigle D; Boughey JC
    Bull Am Coll Surg; 2017 Mar; 102(3):37-8. PubMed ID: 28920661
    [No Abstract]   [Full Text] [Related]  

  • 36. Discovery of drug resistance biomarker could improve cancer treatment.
    Pharmacogenomics; 2013 Jan; 14(2):125. PubMed ID: 23447824
    [No Abstract]   [Full Text] [Related]  

  • 37. Severe acute interstitial lung disease induced by crizotinib therapy in a patient with c-Met amplification non-small cell lung cancer.
    Ji Y; Zhang Z; Nie K; Lan K; Geng C; Liu S; Zhang L; Zhang Z; Sun L; Zou X
    Chin Med J (Engl); 2014; 127(8):1600. PubMed ID: 24762619
    [No Abstract]   [Full Text] [Related]  

  • 38. Targeted therapy in nonsmall cell lung cancer.
    Puri T
    Indian J Cancer; 2017; 54(1):83-88. PubMed ID: 29199670
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Type III or allosteric kinase inhibitors for the treatment of non-small cell lung cancer.
    Fasano M; Della Corte CM; Califano R; Capuano A; Troiani T; Martinelli E; Ciardiello F; Morgillo F
    Expert Opin Investig Drugs; 2014 Jun; 23(6):809-21. PubMed ID: 24673358
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Progress in research on screening and genetics in lung cancer.
    Hirsch FR; Bunn PA
    Lancet Respir Med; 2014 Jan; 2(1):19-21. PubMed ID: 24461890
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.